In the third episode of the series with Perry N. Halkitis, PhD, MS, MPH, he discusses how human behavior as well as other factors play a significant role in repeating outbreaks.
|Videos|July 28, 2017
Treating HIV Today vs the 1980s: One Doctor's Perspective
Author(s)Contagion Editorial Staff
Kathleen Squires, MD, explains how HIV treatment has changed since the 1980s.
Advertisement
Kathleen Squires, MD, Professor and Director, Infectious Diseases, Thomas Jefferson University; and study investigator for the DRIVE-AHEAD Phase 3 clinical trial, explains how HIV treatment has changed since the 1980s.
Interview Transcript (slightly modified for readability):
“It’s been a sea change. In the 1980s, when we had very few drugs available to us, the time between diagnosis and death was a relatively short period of time. One of the best things that we could do for our patients was to help them to die a good death; to be pain-free, and [give them] whatever things that they needed to deal with it. But, now, we are in an era where, hopefully, we diagnose patients in the early stages of HIV infection. We get them on, in many cases, 1 pill a day, and the life expectancy, especially for someone who is diagnosed at a younger age, is almost normal. For someone like me, it really has been an incredible journey to watch this transition.”
Advertisement
Related to this article
In the second episode of the series with Perry N. Halkitis, PhD, MS, MPH, he brings his personal experience to this topic and questions whether there should be a shift in who manages the primary care needs of these patients.
Here is a review of glucagon-like peptide-1 receptor agonist use in people with HIV.
In the first episode of our news series looking at the food safety network, Lynette Johnston, PhD, offers insights into how the federal government surveillance infrastructure operates, and how epidemiologists serve as food detectives in determining bacterial pathogens and potential foodborne outbreaks.
New gyrA testing guides ciprofloxacin use for gonorrhea, cutting ceftriaxone reliance while tackling resistance, access, and FDA hurdles.
Food expert Lynette Johnston, PhD, provides some context around the ongoing outbreak, discusses prevention, and compares 2026 food recalls with previous years.
The Peggy Lillis Foundation will host its 17th Annual Changing the Odds Gala this month in New York City, and it will include a casino, fellowship amongst the C diff community, and an award ceremony honoring a physician-scientist, philanthropist, a researcher, and a patient advocate for their contributions to C difficile awareness, treatment, and prevention.
Resistance-guided testing targeting a single gene mutation could let clinicians safely reintroduce ciprofloxacin for the majority of gonorrhea cases still susceptible to it, sparing ceftriaxone as resistance climbs worldwide. Lao-Tzu Allan-Blitz, MD, MPH, offers insights into his work in this area.
Advertisement
Advertisement